UNRESECTABLE HEPATOCELLULAR CARCINOMA

This early-phase study is testing whether combining two drugs (atezolizumab and bevacizumab) with targeted radiation (SBRT) is safe and tolerable for people with liver cancer that cannot be surgically removed. About 20 participants will receive the combination treatment. The goal…

This study tests a powerful combination of internal radiation and four drugs (nivolumab, ipilimumab, lenvatinib) in people with liver cancer that cannot be removed by surgery. The goal is to see if this approach is safe and can shrink tumors or help people live longer. About 33 p…

This study is for people with advanced liver cancer that cannot be removed by surgery. It tests a treatment that uses the patient's own immune cells, trained in a lab to attack the tumor, combined with immunotherapy drugs and a pneumonia vaccine, all given after high-dose radiati…

This study tests a new medicine, PF-08634404, given alone or with another drug (ipilimumab) for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and shrinks tumors. About 138 participants will receive the drug throug…

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed and has already been treated with …

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This pilot study tests a new approach for people with liver cancer that cannot be removed by surgery. The goal is to see if combining immunotherapy with targeted radiation can shrink the tumor enough to allow surgery. About 30 participants will be enrolled at the University of Ho…

This study tests whether adding two drugs (camrelizumab and apatinib) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be surgically removed. The trial involves 101 adults with intermediate or advanced liver cancer who have not had pr…

This study tests whether combining the drug regorafenib with a type of internal radiation (Y-90) can control advanced liver cancer that cannot be removed by surgery. About 30 adults with unresectable hepatocellular carcinoma will receive the combination. The goal is to see how ma…